Teneligliptin 20 mg + Metformin 500 mg ER (Tab)

Product Overview

YASFORMIN-T is an advanced oral antidiabetic formulation containing Teneligliptin 20 mg and Metformin HCL ER 500 mg. Teneligliptin operates as a competitive DPP-4 inhibitor to prevent the degradation of endogenous incretin hormones (GLP-1 and GIP), enhancing glucose-dependent insulin secretion and suppressing glucagon. Metformin ER activates AMPK pathways, decreasing hepatic gluconeogenesis, delaying intestinal glucose absorption, and enhancing peripheral insulin sensitivity.
Designed for smooth all-day blood sugar management, this extended-release tablet prevents the breakdown of natural gut hormones that prompt insulin release after meals. Simultaneously, it stops the liver from releasing extra stored sugar into the bloodstream.
Developed under stringent quality standards, YASFORMIN-T ensures consistent efficacy, safety, and patient compliance — empowering physicians to achieve optimal therapeutic outcomes in Type 2 Diabetes Mellitus.

Provides dual mechanism—enhanced insulin secretion and improved insulin sensitivity.
DPP-4 inhibition ensures better postprandial glucose control without causing weight gain.
Sustained-release formulation improves glycemic stability and reduces GI discomfort.
Proven to deliver significant HbA1c reduction with excellent safety and tolerability profile.

Each film-coated tablet contains:

Offers complementary glucose-lowering actions for holistic diabetes management.
Once-daily dosing simplifies therapy and enhances patient adherence.
Demonstrated efficacy in reducing glycemic variability and preventing long-term complications.
Supported by clinical evidence for safety in renal and cardiovascular risk patients.

Part of Yaselle Diaxen – Diabetes & Endocrine Care Division
Committed to advancing endocrine health through evidence-based innovation.